---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-23-000101"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:40:08.222750+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exagen Q3 rev $13.4M, net loss narrows to $5.4M; guides FY rev at least $50M

## Summary
- Revenue $13.4M vs $14.7M YoY (included $3.7M one-time Medicare); net loss $(5.4)M vs $(8.1)M.
- Adj. EBITDA improved to $(3.6)M from $(6.1)M YoY; gross margin 57.4% vs 59.2%.
- Cash $28.4M at Sep 30, $31.4M at Oct 31; AVISE CTD ASP $320.
- FY 2023 guidance: rev ≥$50M (record), adj. EBITDA ~$(20)M; expects improvement in 2024.
- Exclusive license with Johns Hopkins to develop lupus nephritis biomarkers.

## SEC filing metadata
- accession: 0001274737-23-000101
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/0001274737-23-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/exdx-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-23-000101
- JSON: https://secwatch.observer/filing/0001274737-23-000101.json
- Plain text: https://secwatch.observer/filing/0001274737-23-000101.txt

## Key facts
- Earnings Releases
  EXAGEN INC. reported the three and nine months ended September 30, 2023 results: revenue $13.4 million, net income $(5.4) million. Guidance reaffirmed.
  - Period: the three and nine months ended September 30, 2023
  - Revenue: $13.4 million
  - Net income: $(5.4) million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. • Recognized total revenue of $13.4 million for the third quarter of 2023. • Delivered gross margin of 57.4% for the third quarter of 2023. • AVISE® CTD trailing twelve-month average selling price (ASP) of $320. • Net loss
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/0001274737-23-000101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.